AI: To Buy or Not to Buy

Shortly after General Electric spun off its HealthCare division, the newly released company started buying AI technology. To share some strategic insights, Digital Science’s IFI CLAIMS Patent Services has taken a look at the target companies’ patents to see what capabilities they’re bringing into the medical technology company.

The phrase ‘patently obvious’ is used in many contexts, from political exchanges to newspaper op-ed columns. Curiously, it is rarely used in the realm of actual patents, but in the case of General Electric’s (GE) HealthCare division, its use seems entirely appropriate.

In early 2023, GE made the decision to spin off GE HealthCare, and immediately following the move the new entity started its M&A strategy by acquiring two companies of its own – Caption Health and IMACTIS. At this early stage, is it possible to infer whether these were sound investments? Six months later, there is still a way to go before full year financial results are posted along with other financial data. However, Digital Science company IFI CLAIMS Patent Services – a global patent database provider for application developers, data scientists, and product managers – can gain insights by looking into the patents the newly enlarged GE HealthCare now holds.

Patents = Strategic Insights

It should be ‘patently obvious’, but checking companies’ patents can be a part of any due diligence process before an investment decision is made. Not only does this help understand risk and technology overlaps, it can also be used to determine where R&D efforts are currently focused in the target acquisition, and in turn set the strategy for the newly merged entity. Analyzing a company’s patent holdings in the midst of M&A dealings provides insights, such as: 

• Strategic direction of companies (i.e., such as the extent to which they are making strides in AI)
• Unique takes on M&A transactions as it is possible to determine – based on companies’ technologies – if core competencies overlap or not with the acquiring company
• Ascertaining if a company’s core competencies are enhanced or not by the acquisitions it’s made

IFI’s latest acquisition report takes a look at GE HealthCare’s acquisitions of IMACTIS and Caption Health’s patented technologies to determine the innovative direction of the company.

‘A good fit’

So what insights can be gleaned from patent data about GE HealthCare and its nascent M&A strategy? According to the report, the acquisition of Caption Health and IMACTIS were a ‘good fit’ for GE HealthCare. Both the acquisitions point towards GE HealthCare’s continued growth in terms of both AI and the application of AI to its existing core technologies. Specifically:

• IMACTIS is a tech healthcare company that offers, among other things, the provision of 3D virtual imaging to surgical navigation
• Caption Health focuses on providing AI capabilities and image data generation to ultrasound technologies

You can see from the chart below that GE HealthCare competes with a number of major companies in establishing AI-related patents, which surged in 2019-2020 before dipping in 2021. As such, the acquisitions in the early part of 2023 of companies that are focused on technology and AI in particular seem to be a good strategic move, especially given the furore around AI technology since late 2022.

Competitive landscape for AI patent applications. Source: https://www.ificlaims.com/news/view/blog-posts/the-ifi-deal-ge-healthcare.htm

What the data says

The report concludes that both Caption Health and IMACTIS make sense for GE HealthCare for several reasons. In the current competitive climate, Caption Health adds necessary AI capabilities while IMACTIS adds new dimensions to the suite of patents it has with 3D virtual images. So overall, it’s a gold star for GE HealthCare when it comes to enhancing its patent – and future commercial – strategy. Isn’t that obvious?

Top patented concepts by Caption Health. Source: https://www.ificlaims.com/news/view/blog-posts/the-ifi-deal-ge-healthcare.htm

Top patented concepts by IMACTIS. Source: https://www.ificlaims.com/news/view/blog-posts/the-ifi-deal-ge-healthcare.htm

Three key takeaways

1. Digital Science’s IFI CLAIMS Patent Services – a global patent database provider for application developers, data scientists, and product managers – can help customers gain insights by looking into the patents held by firms, such as newly enlarged GE HealthCare.

2. IFI’s latest acquisition report takes a look at GE HealthCare’s acquisitions of IMACTIS and Caption Health’s patented technologies to determine the innovative direction of the company – the report concludes that both Caption Health and IMACTIS make sense for GE HealthCare for a number of reasons.

3. Checking companies’ patents should be a part of any due diligence process before any corporate investment decision is made, especially in pharmaceuticals sector.

Contact the IFI CLAIMS team

About the Author

Simon Linacre, Head of Content, Brand & Press | Digital Science

Simon has 20 years’ experience in scholarly communications. He has lectured and published on the topics of bibliometrics, publication ethics and research impact, and has recently authored a book on predatory publishing. Simon is an ALPSP tutor and has also served as a COPE Trustee.

The post AI: To Buy or Not to Buy appeared first on Digital Science.

from Digital Science https://ift.tt/HtGnMQ2

The State of Open Data 2023: A more analytical approach provides unparalleled insights

Digital Science, Figshare and Springer Nature are proud to publish The State of Open Data 2023. Now in its eighth year, the survey is the longest-running longitudinal study into researchers’ attitudes towards open data and data sharing. 

The 2023 survey saw over 6,000 responses and the report that has now been published takes an in-depth look at the responses and purposefully takes a much more analytical approach than has been seen in previous years, unveiling unprecedented insights.

Read the full report

Five key takeaways from The State of Open Data 2023

Support is not making its way to those who need it

Over three-quarters of respondents had never received any support with making their data openly available. 

One size does not fit all

Variations in responses from different subject expertise and geographies highlight a need for a more nuanced approach to research data management support globally. 

Challenging stereotypes

Are later career academics really opposed to progress? The results of the 2023 survey indicate that career stage is not a significant factor in open data awareness or support levels. 

Credit is an ongoing issue

For eight years running, our survey has revealed a recurring concern among researchers: the perception that they don’t receive sufficient recognition for openly sharing their data. 

AI awareness hasn’t translated to action

For the first time, this year we asked survey respondents to indicate if they were using ChatGPT or similar AI tools for data collection, processing and metadata creation. 

Diving deeper into the data than ever before 

This year, we dive deeper into the data than ever before and look at the differing opinions of our respondents when we compare their regions, career stages, job titles and subject areas of expertise. 

Figshare founder and CEO Mark Hahnel said of this approach, “It feels like the right time to do this. Whilst a global funder push towards FAIR data has researchers globally moving in the same direction, it is important to recognize the subtleties in researchers’ behaviors based on variables in who they are and where they are.”

This year features extensive analysis of the survey results data and provides an in-depth and unique view of attitudes towards open data. 

This analysis provided some key insights; notably that researchers at all stages of their careers share similar enthusiasm for open data, are motivated by shared incentives and struggle to overcome the same obstacles. 

These results are encouraging and challenge the stereotype that more experienced academics are opposed to progress in the space and that those driving progress are primarily early career researchers. 

We were also able to look into the nuanced differences in responses from different regions and subject areas of expertise, illuminating areas for targeted outreach and support. These demographic variations also led us to issue a recommendation to the academic research community to look to understand the ‘state of open data’ in their specific setting.  

Benchmarking attitudes towards the application of AI 

In light of the intense focus on artificial intelligence (AI) and its application this year, for the first time, we decided to ask our survey respondents if they were using any AI tools for data collection, processing or metadata collection. 

The most common answer to all three questions was,“I’m aware of these tools but haven’t considered it.”

Although the results don’t yet tell a story, we’ve taken an important step in benchmarking how researchers are currently using AI in the data-sharing process. Within our report, we hear from Niki Scaplehorn and Henning Schoenenberger from Springer Nature in their piece ‘AI and open science: the start of a beautiful relationship?’ as they share some thoughts on what the future could hold for research data and open science more generally in the age of AI. 

We are looking forward to evaluating the longitudinal response trends for this survey question in years to come as the fast-moving space of AI and its applications to various aspects of the research lifecycle accelerate farther ahead. 

Recommendations for the road ahead 

In our report, we have shared some recommendations that take the findings of our more analytical investigation and use them to inform action points for various stakeholders in the community. This is an exciting step for The State of Open Data, as we more explicitly encourage real-world action from the academic community when it comes to data-sharing and open data. 

Understanding the state of open data in our specific settings: Owing to the variations in responses from different geographies and areas of expertise, we’re encouraging the academic community to investigate the ‘state of open data’ in their specific research setting, to inform tailored and targeted support. 

Credit where credit’s due: For eight years running, our respondents have repeatedly reported that they don’t feel researchers get sufficient credit for sharing their data. Our recommendation asks stakeholders to consider innovative approaches that encourage data re-use and ultimately greater recognition. 

Help and guidance for the greater good: The same technical challenges and concerns that pose a barrier to data sharing transcend different software and disciplines. Our recommendation suggests that support should move beyond specific platform help and instead tackle the bigger questions of open data and open science practices. 

Making outreach inclusive: Through our investigation of the 2023 survey results, we saw that the stage of an academic’s career was not a significant factor in determining attitudes towards open data and we saw consensus between early career researchers and more established academics. Those looking to engage research communities should be inclusive and deliberate with their outreach, engaging those who have not yet published their first paper as well as those who first published over 30 years ago. 

What’s next for The State of Open Data?  

The State of Open Data 2023 report is a deliberate change from our usual format; usually, our report has contributed pieces authored by open data stakeholders around the globe. This year, we’ve changed our approach and we are beginning with the publication of this first report, which looks at the survey data through a closer lens than before. We’ve compared different subsets of the data in a way we haven’t before, in an effort to provide more insights and actionable data for the community.

In early 2024, we’ll be releasing a follow-up report, with a selection of contributed pieces from global stakeholders, reflecting on the survey results in their context. Using the results showcased in this first report as a basis, it’s our hope that this follow-up report will apply different contexts to these initial findings and bring new insights and ideas. 

In the meantime, we’re hosting two webinars to celebrate the launch of our first report and share the key takeaways. In our first session, The State of Open Data 2023: The Headlines, we’ll be sharing a TL;DR summary of the full report; our second session, The State of Open Data 2023: In Conversation, will convene a panel of global experts to discuss the survey results. 

You can sign up for both sessions here: 

The State of Open Data 2023: The Headlines

The State of Open Data 2023: In Conversation

About the Author

Laura Day, Marketing Director | Figshare

Laura is the Marketing Director at Figshare, part of Digital Science. Before joining Digital Science, Laura worked in scholarly publishing, focusing on open access journal marketing and transformative agreements. In her current role, Laura focuses on marketing campaigns and outreach for Figshare. She is passionate about open science and is excited by the potential it has to advance knowledge sharing by enabling academic research communities to reach new and diverse audiences.

The post The State of Open Data 2023: A more analytical approach provides unparalleled insights appeared first on Digital Science.

from Digital Science https://ift.tt/95O0ABW

Dr. N.S,Kumar, Ghousia College of Engineering, India, Best Researcher Award

Dr. N.S,Kumar, Ghousia College of Engineering, India, Best Researcher Award

International Research Awards on New Science Inventions
Website: nesin.sciencefather.com


Visit Our Conference Nomination: https://x-i.me/nesiabst2
Visit Our Award Nomination: https://x-i.me/GGwW
Contact us: nesin@sciencefather.com

#science #sciencefather #shorts #technology #conference #awards #research #engineering #microbiology #physics #mathematics #arts #management #chemistry #neuroscience #biology #business #genetics #medicine #Pharmacology #economics #toxicology #pharmacology

Dr

Development and external validation of Hybrid 2D/3D UNet

This speech delivered by Dr. Ping Hu, The Second Affiliated Hospital of Nanchang University, China

Deep learning-assisted identification and quantification of aneurysmal subarachnoid hemorrhage in non-contrast CT scans: Development and external validation of Hybrid 2D/3D UNet.

The International Conference on New Science Inventions is probably a platform for experimenters, scientists, masterminds, and originators to present their rearmost advancements and discoveries in the field of wisdom and technology.

International Research Awards on New Science Inventions
Visit:nesin.sciencefather.com
Conference Submission: https://x-i.me/nesiabst2
Award Nomination: https://x-i.me/GGwW
Contact us :nesin@sciencefather.com

#science #sciencefather #shorts #technology #conference #awards #research #engineering #microbiology #physics #mathematics #arts #management #chemistry #neuroscience #biology #business #genetics #medicine #Pharmacology #economics #toxicology #pharmacology

Exploring the Molecular landscape of Catharina Sour Beer: A Fusion of Omics Strategies for Starter and Probiotic Strains Assessment.

This speech delivered by Dear Dr. Marcos Edgar Herkenhoff, University of São Paulo, Brazil

Exploring the Molecular landscape of Catharina Sour Beer: A Fusion of Omics Strategies for Starter and Probiotic Strains Assessment.

The International Conference on New Science Inventions is probably a platform for experimenters, scientists, masterminds, and originators to present their rearmost advancements and discoveries in the field of wisdom and technology.

International Research Awards on New Science Inventions
Visit:nesin.sciencefather.com
Conference Submission: https://x-i.me/nesiabst2 Award Nomination:
Award Nomination: https://x-i.me/GGwW
Contact us :nesin@sciencefather.com

#science #sciencefather #shorts #technology #conference #awards #research #engineering #microbiology #physics #mathematics #arts #management #chemistry #neuroscience #biology #business #genetics #medicine #Pharmacology #economics #toxicology #pharmacology